AGP
VKTX icon

Artia Global Partners’s Viking Therapeutics VKTX Stock Holding History

Artia Global Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.05M Hold
180,731
– – 1.3% 17
2026
Q1 		$5.88M Sell
180,731
-538,634
-75% -$17.3M 1.18% 16
2025
Q4 		$25.3M Buy
719,365
+573,186
+392% +$20.3M 3.59% 6
2025
Q3 		$3.84M Buy
146,179
+49,700
+52% +$1.48M 0.61% 25
2025
Q2 		$2.56M Buy
96,479
+6,200
+7% +$163K 0.62% 22
2025
Q1 		$2.18M Hold
90,279
– – 0.55% 22
2024
Q4 		$3.63M Sell
90,279
-442,600
-83% -$25.2M 1.3% 20
2024
Q3 		$33.7M Buy
532,879
+79,900
+18% +$4.69M 9.2% 3
2024
Q2 		$24M Buy
452,979
+19,399
+4% +$1.27M 4.64% 6
2024
Q1 		$35.6M Buy
433,580
+50,000
+13% +$2.22M 7.15% 5
2023
Q4 		$7.14M Hold
383,580
– – 2.08% 10
2023
Q3 		$4.25M Hold
383,580
– – 1.77% 15
2023
Q2 		$6.22M Buy
383,580
+315,172
+461% +$6.6M 2.14% 19
2023
Q1 		$1.14M Sell
68,408
-62,505
-48% -$646K 0.42% 27
2022
Q4 		$1.23M Buy
+130,913
New +$584K 0.47% 21

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Artia Global Partners's VKTX Position: Q2 2026 in Review

Artia Global Partners held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 180,731 shares worth $7.05M. The position accounts for 1.3% of the portfolio, ranked #17.

Artia Global Partners first reported a position in VKTX in Q4 2022 and has held it in 15 quarters since. The position peaked at $35.6M in Q1 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Artia Global Partners held 180,731 shares of Viking Therapeutics worth $7.05M as of Q2 2026.
  • Artia Global Partners left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up 1.3% of Artia Global Partners's portfolio in Q2 2026, its #17 holding.
  • Artia Global Partners first reported a position in Viking Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Artia Global Partners's Viking Therapeutics position peaked at $35.6M in Q1 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Artia Global Partners's 13F filing for Q2 2026, filed 14 Aug 2026.